AbbVie's Rova-T, BMS combo each show SCLC benefit

Newly presented data showed survival benefits and response rates for Rova-T rovalpituzumab terisine from AbbVie Inc. (NYSE:ABBV) and Opdivo nivolumab as monotherapy and in combination with Yervoy ipilimumab to treat recurrent small cell lung cancer. Bristol-Myers Squibb Co. (NYSE:BMY) markets both Opdivo and Yervoy.

Data from studies of the therapies were presented over the weekend at the American Society of Clinical Oncology (ASCO) meeting. The Rova-T data appeared to fall short of investors' high expectations, as AbbVie shed $2.18 to $62.82 on Monday. ...